Pharmacodynamic Profiles of Ketamine (R)- and (S)- with 5-Day Inpatient Infusion for the Treatment of Complex Regional Pain Syndrome

Michael E. Goldberg, MD¹, Marc C. Torjman PhD¹, Robert J Schwartzman, MD², Donald E. Mager, Pharm.D., PhD³, and Irving W. Wainer, PhD⁴

Background: Ketamine might be effective in blocking central sensitization of pain transmission neurons through its effect on NMDA receptors in refractory Complex Regional Pain Syndrome (CRPS) patients. At higher doses, ketamine infusions can be associated with significant risks; outpatient therapy requires return visits for a 10-day period with variable efficacy and duration.

Objective: This study determined the efficacy of a 5-day moderate dose, continuous racemic ketamine infusion. The pharmacodynamic responses to racemic ketamine and norketamine were examined.

Design: Observational study

Methods: In this study, ketamine was titrated from 10-40 mg/hour in 16 CRPS patients, and maintained for 5 days. Pain was assessed daily. Ketamine and norketamine concentrations were obtained on Day 1 before starting the infusion; at 60 to 90 minutes, 120 to 150 minutes, 180 to 210 minutes, and 240 to 300 minutes after the initiation of the infusion on Days 2, 3, 4, and 5; and on Day 5 at 60 minutes after the conclusion of the infusion. The plasma concentrations of (R)-ketamine, (S)-ketamine, (R)-norketamine and (S)-norketamine were determined using an enantioselective liquid chromatography – mass spectrometry method.

Results: Ketamine and norketamine infusion rates stabilized 5 hours after the start of the infusion. The subjects showed no evidence of significant tachycardia, arterial oxygen desaturation, or hallucinatory responses. Subjects generally experienced minimal pain relief on day one followed by significant relief by day 3. Mean pain scores decreased from the 8-9 to 3-5 ranges; however, the analgesic response to ketamine infusion was not uniform. On day 5, there was little or no change in the pain measure assessed as the worst pain experienced over the last 24 hours in 37% of the subjects. (R)- and (S)-ketamine concentrations peaked at 240-300 min. (R)- and (S)-norketamine concentrations were lower and peaked on Day 2 of the infusion, as opposed to Day 1 for (R)- and (S)-ketamine. Significant pain relief was achieved by the second day of infusion and correlated with the maximum plasma levels of ketamine and norketamine. Pain relief continued to significantly improve over the 5 day infusion at concentrations of 200-225 ng/mL for (R)- and (S)-ketamine, and 90-120 ng/mL for (R)- and (S)-norketamine.

Conclusions: A 5-day ketamine infusion for the treatment of severe CRPS provided significant (P<0.05) pain relief by Day 3 compared to baseline. The pain relief experienced on Day 2 of the infusion continued to improve over the 5-day infusion period and correlated with the maximum plasma levels of ketamine and norketamine. We speculate that downstream metabolites of ketamine and norketamine might be playing a role in its therapeutic efficacy.

Key words: ketamine, norketamine, CRPS, pharmacodynamics, chronic pain, enantiomers

Pain Physician 2010; 13:379-387

www.painphysicianjournal.com
Clinical regional pain syndrome (CRPS) is associated with pain that is out of proportion to the inciting injury, is neuropathic in nature, and is regional in distribution (1). This pain most commonly follows an injury, is often unilateral in its onset, and can spread to the contralateral side at times being generalized (2,3). A factor analysis of the signs and symptoms of CRPS patients revealed 4 distinct clusters: 1) abnormalities in pain processing; 2) autonomic dysregulation; 3) neurogenic edema; 4) a motor dysfunction associated with atrophy and dystrophy (4,5).

There is abundant evidence supporting a dynamic change in the physiology and structure of central pain projecting neurons mediated through the N-methyl-D-aspartate (NMDA) receptor (6-11). A nociceptive barrage initiates and maintains a state of central sensitization in the central pain projecting pathways (7,8). This central sensitization results in a lower threshold to fire pain transmission neurons (PTNs), increases their receptive fields and is associated with thermal and mechanical allodynia and spontaneous pain (9).

A significant percentage of CRPS patients who do not respond to conventional treatment have disease recurrence (12) along with spread of illness from the area of original injury (13). A critical factor in the initiation of central sensitization is the release of the magnesium block of the NMDA receptor that results in calcium influx and the initiation of intracellular enzymatic cascades, thus increasing the excitability of pain transmission neurons (10,11). This observation led to the use of ketamine to block the NMDA receptor in neuropathic pain states.

Ketamine is a chiral compound that is administered as a racemic (50:50) mixture of its enantiomers (R)-ketamine and (S)-ketamine. It has been previously demonstrated that (R)-ketamine and (S)-ketamine have significantly different pharmacodynamic activities since (S)-ketamine is a more potent analgesic agent than (R)-ketamine (14). The post-hypnotic stimulatory properties and agitated behavior observed with ketamine have been associated with (R)-ketamine (15). In addition, ketamine is extensively metabolized by N-demethylation producing norketamine, a non-competitive NMDA receptor antagonist which might also exhibit enantioselective pharmacological activity, e.g. (S)-norketamine has an 8-fold higher affinity than (R)-norketamine in a rat cortical wedge preparation (16).

Clinically, ketamine has shown efficacy in the treatment of neuropathic pain (17), in the reduction of chronic orofacial pain (18), and in acute visceral and cutaneous pain (19). Previous studies also support the effectiveness of ketamine in blocking central sensitization through its effect on the NMDA receptor, and therefore as an effective approach to the treatment of CRPS (20-25). A 5-day low dose ketamine infusion administered in an inpatient setting was shown to be effective in patients with less severe distal disease of one extremity (10). A 5-day continuous infusion of ketamine and midazolam, at coma inducing doses administered in an ICU setting, was also effective in the treatment of patients with intractable pain (26). In addition, outpatient protocols utilizing low dose (40 to maximum of 80 mg) ketamine infusions administered over several days were effective in treating CRPS (23,25). In a recent double blind, randomized, placebo controlled study by Sigtermans and associates, those authors administered the (S) form of ketamine (max dose 22 mg/hour) in patients with CRPS. Although they demonstrated a significant improvement in pain, there was no evidence of a functional improvement, and pain relief was no longer significant by week 12 post (S) ketamine infusion (22).

While these treatments appeared to be efficacious, they are not optimal. In the high dose setting, the infusion can be associated with significant risks including chronic catheterization with the need for parenteral nutrition, and endotracheal intubation. The outpatient therapy requires the patient to return for a 10-day period of time and, though efficacious, generally showed loss of effectiveness after 6-12 weeks.

The current study was designed as an observational study to determine the efficacy and pharmacodynamics of a moderate dose of racemic ketamine administered as an inpatient 5-day continuous infusion.

Methods

Patients

After approval from the Cooper University Institutional Review Board, 16 American Society of Anesthesiologists Physical Status Classification I or II patients with a primary diagnosis of CRPS gave written informed consent to participate in this prospective study.

All 16 patients fulfilled the 1993 IASP-CRPS diagnostic clinical and proposed research modifications (4), as well as the diagnostic criteria proposed at the 2005 Budapest Consensus Conference on CRPS. The patients were recruited from the CRPS clinic at the Department of Neurology of Drexel University College of Medicine by a neurologist (RJS). Cluster analysis of these patients
Placed them in the subgroup of a florid CRPS syndrome (5). No distinction was made between CRPS I and II patients.

The average daily pain intensity was required to be 7 or greater on a numeric rating scale (NRS) in which the endpoints were 0: no pain, and 10 the worst pain imaginable, for at least 6 months while on standard therapy. Patients had to have failed standard pharmacologic therapy (non-steroidal anti-inflammatory drugs [NSAIDs], anti-epileptic drugs [AEDs], narcotics, antidepressants), interventional (sympathetic nerve blocks or, in some patients, dorsal column stimulators or morphine pumps), as well as physical therapy and psychiatric care. Failure was defined as: 1) no benefit from treatment; or 2) pain relief lasting no longer than 6 weeks; 3) recurring, persisting or progression of disease.

Exclusion criteria included allergies to ketamine, clonidine, midazolam, or known contraindications to ketamine use which include severe arterial hypertension, hyperthyroidism, ischemic heart disease, or heart failure. Patients were excluded who had a history of substance or drug abuse or suspected somatoform pain disorder. All patients had psychiatric and cardiac clearance which included echocardiography (ECG), Holter monitoring studies, and a detailed neuropsychological battery prior to treatment. Inclusion and exclusion criteria were validated by a neurologist (RJS) and an anesthesiologist (MEG) prior to entry into the study.

**Treatment Protocol**

Patients were admitted to a monitored telemetry unit (continuous ECG and pulse oximetry) and maintained on their usual pain medications during the infusion period. The patient demographic data are presented in Table 1.

Ketamine was mixed in a 500 mL bag of normal saline and started at an infusion rate of 10 mg/hour and titrated to a maximum of 40 mg/hour to achieve comfort without evidence of significant side effects or oxygen desaturation (< 92%). Transdermal clonidine 0.1 mg/day was administered to block sympathomimetic, psychomimetic, and potential neurotoxic ketamine side effects (26). Midazolam was administered using a 2 to 4 mg dose every 4 hours if patients were unduly

---

**Table 1.** The demographic data are presented for the 16 subjects with the baseline pain scores in the fifth column. The means and standard deviations are below the table.

<table>
<thead>
<tr>
<th>Subject number</th>
<th>Age (years)</th>
<th>Height (cm)</th>
<th>Weight (kg)</th>
<th>0-10 Pain level pre dosing</th>
<th>0-10 Pain level Day 5</th>
<th>% Change Pain level Day 1-5</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>26</td>
<td>182.9</td>
<td>81.8</td>
<td>4</td>
<td>1</td>
<td>75</td>
</tr>
<tr>
<td>2</td>
<td>25</td>
<td>157.5</td>
<td>51.8</td>
<td>8.5</td>
<td>7.5</td>
<td>13</td>
</tr>
<tr>
<td>3</td>
<td>41</td>
<td>156.2</td>
<td>118.2</td>
<td>8</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>4</td>
<td>18</td>
<td>170.2</td>
<td>61.4</td>
<td>8</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>20</td>
<td>160.0</td>
<td>53.1</td>
<td>10</td>
<td>5</td>
<td>50</td>
</tr>
<tr>
<td>6</td>
<td>40</td>
<td>167.6</td>
<td>52.3</td>
<td>8</td>
<td>7</td>
<td>10</td>
</tr>
<tr>
<td>7</td>
<td>44</td>
<td>170.2</td>
<td>62.0</td>
<td>8</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>8</td>
<td>25</td>
<td>160.0</td>
<td>50.0</td>
<td>7</td>
<td>4</td>
<td>43</td>
</tr>
<tr>
<td>9</td>
<td>17</td>
<td>157.5</td>
<td>72.7</td>
<td>7</td>
<td>2</td>
<td>71</td>
</tr>
<tr>
<td>10</td>
<td>42</td>
<td>175.3</td>
<td>56.8</td>
<td>10</td>
<td>6</td>
<td>40</td>
</tr>
<tr>
<td>11</td>
<td>38</td>
<td>165.1</td>
<td>77.3</td>
<td>10</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>12</td>
<td>47</td>
<td>167.6</td>
<td>77.7</td>
<td>10</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>13</td>
<td>36</td>
<td>162.6</td>
<td>73.2</td>
<td>10</td>
<td>2</td>
<td>80</td>
</tr>
<tr>
<td>14</td>
<td>45</td>
<td>177.8</td>
<td>93.6</td>
<td>10</td>
<td>4</td>
<td>60</td>
</tr>
<tr>
<td>15</td>
<td>37</td>
<td>165.1</td>
<td>62.3</td>
<td>10</td>
<td>7</td>
<td>30</td>
</tr>
<tr>
<td>16</td>
<td>27</td>
<td>162.6</td>
<td>41.5</td>
<td>8</td>
<td>3</td>
<td>63</td>
</tr>
</tbody>
</table>

**Means** | 33.0 | 166.1 | 67.9 | 8.5 | 5.4 |
**SD**   | 10.2 | 7.7  | 19.3 | 0.4 | 0.8 |
restless, dysphoric, or hallucinating. The infusion was
maintained for 5 days with 24-hour monitoring of the
subject. During the titration period, an advanced prac-
tice nurse and a research assistant collected the study
data and blood samples.

Pain Assessments

The patients rated their pain intensity daily using a
0-10 numerical scale (0 no pain, 10 worst pain imagin-
able). The patients were asked to provide a measure of
their overall pain relief using 0 percent as no relief, and
100 percent as complete pain relief, compared to their
pain prior to the start of the infusion. These measure-
ments were selected to provide assessments of not only
pain intensity, but also about the subject’s perceived
treatment effectiveness by quantifying the relief they
experienced after treatment. The pain assessments were
obtained by an experienced pain nurse on the morning
of each day at approximately 10 am, and on the last day
within one hour after termination of the infusion.

Ketamine Blood Levels

Blood samples (7 mL) were obtained on Day 1 be-
fore starting the infusion, and at 60 to 90 minutes, 120
to 150 minutes, 180 to 210 minutes, and 240 to 300 min-
utes after the initiation of the infusion, on Days 2, 3, 4,
5 (morning collection), and on Day 5 at 60 minutes after
the conclusion of the infusion. The samples were centri-
fuged and the plasma collected and frozen at -80°C un-
til analysis. The plasma concentrations of (R)-ketamine,
(S)-ketamine, (R)-norketamine and (S)-norketamine
were determined using a previously reported enanti-
oselective liquid chromatography – mass spectrometry
method (27).

Statistical Analyses

Sample size was determined using a power analysis
for paired T-test based on an achieved pain reduction
of 0.5 (SD = 0.4) from baseline to the end of treatment
on Day 5. This level of pain reduction was based on pri-
or experience, as well as others having achieved similar
levels of analgesia in a comparable patient population.
With 16 data pairs the study had a power of 80.1% to
yield a statistically significant result. Pain and blood
level data measured across time were analyzed using
ANOVA with repeated measures. Post hoc analysis was
used to compare differences between means after con-
firming significant main effects, and a P <0.05 was con-
sidered statistically significant. Demographic data are
presented as means ± standard deviation while pain
and drug blood levels data as means ± standard er-
ror of the mean. The analyses were performed using
Systat Software version 11.00.01 (Systat Software Inc.,
Chicago, IL).

Results

Patient characteristics

The patients in this study included 15 females and
one male ages 17-47 years (mean 33±10.2), height
156.2-182.9 cm (mean 166.1 ± 7.7) and weight 41.5-
118.2 kg (mean 67.9 ± 19.3) (Table 1). The mean base-
line pain level was 8.5 ± 1.6 assessed as the worst pain
experienced over the last 24 hours prior to dosing using
a 0-10 categorical pain scale (Table 1).

Clinical Response

All of the patients tolerated the infusions without
difficulty. The ketamine infusion rate was gradually
increased from 10 to 40 mg/hour for all patients after
which a stable ketamine infusion rate was achieved ap-
proximately 5 hours after the start of infusion (Fig. 1).
The patients showed no evidence of clinically signifi-
cant tachycardia (HR >100 bpm), arterial oxygen desat-
uration (SpO2 < 92%), or hallucinatory responses. Each
subject received at least 2 mg of midazolam during the
initial titration phase (Day 1), and 13/16 (81%) patients
had a clonidine patch (0.1 mg dose) applied for the du-
ration of their 5-day hospital stay. None of the patients
required removal of the clonidine patch subsequent to
hypotension. The patients were maintained on their
outpatient medications with no changes in dosing ex-
ccept for opioid medications that were titrated to lower
doses by Day 5.

In general, the patients experienced minimal pain
relief on Day 1 followed by significant relief by day 3.
Mean pain intensity gradually decreased from 8.5 ± 0.4
(Day 1) to 5.4 ± 0.8 (Day 5), P <0.001 over the 5-day
period (Fig. 2). The decreased pain levels corresponded
to a gradual increase in overall daily pain relief which
reached statistical significance (P <0.05) on Day 4 (Fig.
3). However, the response to the ketamine infusion was
not uniform. On Day 5, there was little or no change
in the pain measure, assessed as the worst pain expe-
rienced over the last 24 hours, in 6 of the 16 patients
(37.5%) (Table 1).

Ketamine Blood Concentrations

Serial blood samples were obtained from all of the
patients in the study and complete profiles were ob-
Fig. 1. This figure illustrates the mean ± SEM infusion rates for each day over the 5 day treatment period.

Fig. 2. This figure illustrates the mean ± SEM pain scores (0-10 scale) for the 5-day treatment period. The * symbol indicates statistical significance versus baseline and Day 1 pain scores.
tained for 13/16 patients. The samples were analyzed using a validated assay and (R)-ketamine, (S)-ketamine and their respective N-demethylated metabolites, i.e. norketamine, were detected and quantified. The average (R)- and (S)-ketamine plasma concentrations peaked at 240-300 minutes after the start of the infusion and were significantly ($P < 0.05$) increased from baseline at all time points (Fig. 3). A similar trend was noted for the average (R)- and (S)-norketamine plasma concentrations, although those were lower and peak concentrations were only reached on Day 2 of the infusion, as opposed to Day 1 for (R)- and (S)-ketamine (Fig. 3).

Significant pain relief was achieved by the second day of infusion and correlated with the maximum plasma levels of ketamine and norketamine. The pain relief continued to be significant and improve over the 5-day infusion at concentrations of 200-225 ng/mL for (R)- and (S)-ketamine, and 90-120 ng/mL for (R)- and (S)-norketamine. Both norketamine plasma levels peaked approximately 24 hours later than the ketamine plasma levels and were near the same concentration at the termination of the infusion (Fig. 3). It appears that once stable blood levels of ketamine and norketamine are achieved, pain relief rapidly ensues and continues during the course of the infusion.

**Discussion**

The data from this study indicate that a 5-day continuous infusion of moderate (subanesthetic) dose ketamine significantly reduces pain levels 3 days after the
start of the infusion. Although the analgesic response is consistent with our previous findings using a 10-day low dose outpatient ketamine infusion (25), the data from the present study point to more profound pain relief with the 5-day infusion compared to our low dose 10 day infusion (mean pain scores at end of infusion 2.8 ± 0.65 vs. 5.44 ± 0.91, respectively). The 5-day moderate dose ketamine therapy used in this study provided significant reduction (≥ 30%) in the perceived pain level in 10/16 patients compared to baseline Day 1 pain scores, although 6/16 patients reported no significant pain reduction (≤ 15%) (Table 1). In addition, we noted large inter-patient variability in pain responses in the patients who could be considered to have benefited from the treatment (Table 1). This inter-patient variability in the antinociceptive response produced by ketamine has been previously reported by Rabben et al (18) in patients with trigeminal neuropathic pain. In their study (18), 26 patients were evaluated after receiving a single intramuscular injection of ketamine (0.4 mg/kg) and 3 different response patterns were observed: 1) long-term (6 to 24 hours) pain relief in 8/26 patients, 2) short term (< 2 hours) pain relief in 9/26 patients, and 3) no pain relief in 9/26 patients. The relative pain relief provided in the 3 sub-populations was determined as a percentage of the baseline pain score which also demonstrated that the degree of pain relief varied among the 3 groups.

The observation of 3 qualitatively different response groups led Rabben et al (18) to postulate that the data did not support the paradigm of NMDA receptor-mediated sensitization as a universal mechanism of neuropathic pain. Other studies have suggested that the beneficial effects on inflammatory pain are NMDA mediated while those on acute, non-inflammatory pain involve a periaqueductal gray matter descending inhibitory system (28) and also differ based upon the source of the pain (19). In addition to the NMDA receptor blockade, ketamine also interacts with a number of other receptors including opioidergic, cholinergic and monoaminergic pathways, all of which could play a role in the analgesic response (19). In this study, the exact role of NMDA receptors in the observed responses could not be determined, nor was the role that other families of receptors might play. The presence and therapeutic significance of single nucleotide polymorphisms (SNPs) of the NMDA receptor cannot be overlooked and opens new grounds for research.

This study also reports the blood levels of (R)-ketamine, (S)-ketamine, (R)-norketamine and (S)-norketamine following an extended infusion. Our data are consistent with the results of previous studies involving single administrations of the racemic drug (28,29).

In a recent study (22), the (S) enantiomer of ketamine was utilized in a placebo controlled, double blind protocol to treat patients with chronic CRPS who had refractory pain. The infusion rate was somewhat lower (22mg/h/70kg vs 40 mg/h independent of weight) and the plasma concentrations of (S) ketamine and (S) norketamine achieved were similar (22) (peaked at 250ng/mL and 225 ng/mL, respectively). Our study utilized the racemic mixture which is commonly used in the United States. The plasma concentrations of (R) and (S) ketamine and (R) and (S) norketamine did not differ significantly from one another (Fig. 3).

Our study did not include a placebo group because of the ethical dilemma concerning withheld treatment in this population. Those patients have typically exhausted other therapies and would most likely be able to identify placebo versus active treatment due to the psychomimetic effects of ketamine. To construct a sham group with a drug such as midazolam, would be easier in the low dose setting where the effects of ketamine are not as pronounced (23). In the in-patient setting with a moderate ketamine dose, the midazolam dosing, or that of other medications to mimic this effect, would expose the patients to significant risk. It is interesting to note that despite the lack of a control group, our results are quite similar to those of Sigtermans et al (22).

At the present time, ketamine and norketamine are considered to be the active agents responsible for the antinociceptive response produced by the administration of racemic-ketamine, with the activity primarily residing in the (S)-enantiomers of these compounds. This assumption is based upon the observations that (S)-ketamine is a more potent analgesic agent than (R)-ketamine (14), that (S)-norketamine has an 8-fold higher affinity than (R)-norketamine in a rat cortical wedge preparation (16), and the recent data from a study utilizing a rat model of peripheral neuropathy which demonstrated that the antinociceptive properties of norketamine are due to (S)-norketamine (29).

Although the current study involved a limited number of patients, we cannot discount the possibility that the systemic administration of ketamine and norketamine might not be responsible for all of this drug’s antinociceptive properties. The varied responses to treatment observed in this study, and in the study of Rabben et al (18) might not reflect a different mecha-
nism of pain, but rather inter-individual differences in the ability to metabolize ketamine, i.e. pharmacogenetic differences, as was observed between European and Japanese patients (31). Thus downstream metabolites of ketamine and norketamine might be playing a role in its therapeutic efficacy.

It is, however, encouraging to note that our findings are similar to the previously described placebo controlled trial (22) where pain relief is not dependent on the dose administered. The search to identify the active metabolite(s) should continue, as well as what effect a longer infusion might have on pain relief in these patients.

Acknowledgments

The authors thank Ms. Jessie Dotson, RN, CNP, for her assistance with the data collection and for her excellent care of every study subject. The authors also wish to thank the editorial board of Pain Physician for review and criticism in improving the manuscript.

References


16. Ebert B, Mikkelsen S, Thorkildsen C, and Borgbjerg FM. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 1997; 333:99-104.


24. Koffler SP, Hampstead BM, Iranif F, Tinker J, Kiefer RT, Rohr P, Schwartzman RJ. The neurocognitive effects of 5 day an-


